Answers are grounded in this paper and cite their sources.
Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically significant improvement in overall survival for patients with advanced hepatocellular carcinoma (HCC).However, there were few cases of partial or complete response reported in the previous studies.We herein report a case of dramatic partial response in a patient who had advanced HCC with multiple lung metastasis and portal vein thrombosis treated with sorafenib.(J Liver Cancer 2016;16:57-62)
No takes yet. Share an insight, caveat, or question.
Kim et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: